Related Experiment Video

Updated: Jun 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statin-fibrate combination for mixed dyslipidaemia: a limited option?

Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis

    Current Medical Research and Opinion
    |July 29, 2010
    PubMed

    Insights

    Combining statins and fibrates offers better lipid control for mixed dyslipidemia than monotherapy alone. While safe, more data is needed to confirm clinical benefits for widespread use.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Metabolic Disorders

    Background:

    • Aggressive statin therapy often fails to eliminate residual cardiovascular risk, especially in patients with mixed dyslipidemia.
    • Mixed dyslipidemia, characterized by abnormal levels of multiple blood lipids, poses a significant health challenge.

    Discussion:

    • Combination therapy with statins and fibrates demonstrates superior efficacy in managing various lipid parameters compared to monotherapy.
    • This combination therapy exhibits a safety profile comparable to individual statin or fibrate treatments.

    Key Insights:

    • Statin-fibrate combination therapy is a potential therapeutic strategy for specific patients diagnosed with mixed dyslipidemia.
    • The observed clinical benefits of this combination have been limited to small subgroup analyses.

    Outlook:

    • Further large-scale clinical trials are necessary to validate the broader clinical utility and efficacy of statin-fibrate combination therapy.
    • Wider implementation in clinical practice requires more robust evidence regarding long-term patient outcomes.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

    Blood Studies for Cardiovascular System III: Serum Lipid Profile

    Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
    Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
    Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...